As the commercialization and approval of CAR-T therapies continues to gain momentum, the leaders are working to globalize the delivery of “curative” CAR-T and TCR therapies to beyond the Western world. Asia, as one of the world’s largest economies will serve as a cornerstone for the development and delivery of novel cellular immunotherapies.
The CAR-TCR Summit Asia is the dedicated platform focused on ensuring the clinical translation of CAR-T and TCR therapies to the market globally, ensuring affordability and accessibility to all those in need.
Join the leaders in therapeutic drug development as they discuss the latest clinical data emerging in Asia, focussing on the affects of ethnicity on safety and efficacy. Discover the novel targets beyond CD19 being utilized for solid tumor indications. Discuss the next generation technologies being used to automate manufacturing and reduce the CoGs to increase the affordability of CAR-TCR therapies worldwide.
"Well organized conference that brought the leading researchers and sponsors together to discuss topics highly relevant to the field. Well done."
-Kenneth Miller, Sr Director, New Business Development, Abbvie, CAR-TCR 2017 attendee
"I can't speak highly enough about this conference. This conference allowed me to keep informed of the latest research and development on T cell therapies. I was also able to network with some of the leaders in T cell immunotherapies from both academia and the industry."
-Arnab Ghosh, Hematology & Medical Oncology Fellow, MSKCC, CAR-TCR 2017 attendee